Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated in use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004. It is grouped under the following drug class(es): Antineoplastic agents and Cytotoxics. Its therapeutic use is listed as anti-cancer agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Alimta and Pemfexy. Its PubChem CID is 135410875.
Pemetrexed
| CAS No | 137281-23-3 |
|---|---|
| Molecular Formula | C20H21N5O6 |
| Molecular Weight | 427.4 g/mol |
| Synonyms | (2S)-2-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta.
The listed CAS number is 137281-23-3.
The listed molecular formula is C20H21N5O6.
The listed molecular weight is 427.4 g/mol.
(2S)-2-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid.
The source lists Alimta and Pemfexy.